胰岛素样生长因子结合蛋白、内毒素与肝纤维化

目前胰岛素样生长因子结合蛋白（insulin—like growth—factor—binding protein，IGFBPs）及其超家族功能的研究是国际上的热点。有研究表明IGFBPs与肝纤维化的发生有关，而临床检测和动物实验表明肠源性内毒素血症与肝纤维化的发生发展有着密切关系，同时有研究显示内毒素可诱导循环中某些IGFBPs和其肝脏基因的表达发生变化。     

TQ-2000多通道剂量仪在TBI体内相对剂量测量中的应用

全身照射(TBI)前,各放射治疗部门将针对本单位的设备、机房环境等实际情况,拟定相应的物理照射技术,进行必要的物理参数的测量.CDP仿真人体模型与TQ-2000多通道剂量仪的配合使用,可以快速、准确地测量TBI中体内相对剂量有关数据,为临床治疗提供质量保证.     

Therapeutic effect of 5-FC on YCD modified murine P388 leukemia in vivo

Cytosine deaminases (CDs) in bacteria andfungi are found to deaminate prodrug 5 - FC intocytotoxic agent 5 - FU .Yeast CD (YCD) is clonedfrom Saccharomyces cerevisiae.It has been shownpreviously that YCD was more efficient inconversing5 - FC than bacterial CD(b CD) [1-3 ] .As anovel suicide gene therapy system,YCD/ 5 - Fcsystem may be promising in cancer therapy andprevention of graft versus host disease.In thepresent study,we established a P388/ DBA murineleukemia model by infusin…     

128例肾输尿管结石临床分析

目的为探讨肾输尿管结石的临床特点,以提出更好的防治措施。方法对原西南师范大学医院1997-2004年治疗的128例肾输尿管结石病例的临床资料进行统计分析。结果本组病例男女之比为2.05∶1,29岁以下发病103例,占80.5%。2001年起发病呈上升趋势,2003年最高。每年9-10月是发病高峰,占本组病例的31.2%。经体外震波碎石99例,3个月结石排净率为83%,与文献报道的基本一致。结论该校肾输尿管结石患者,男性多于女性,30岁以下居多。发病近年增加,体外震波碎石疗效好。     

中药灌肠治疗慢性肾功能不全的近期疗效观察

目的探讨以生大黄为主的中药保留灌肠治疗慢性肾功能不全的确切疗效。方法对324例临床确诊为慢性肾功能不全的患者，在内科保守治疗的基础上加用以生大黄为主的中药保留灌肠，每晚1次，4周为1疗程，通过观察治疗前后肾功能的变化评价疗效。结果疗程结束后，氨质血症及尿毒症早期患者的BUN、Ser较治疗前明显降低（P＜0.05），胃肠道症状明显改善。对终末期尿毒症患者的临床症状及肾功能指标改善不明显。结论以生大黄为主的中药保留灌肠对氨质血症及尿毒症早期疗效肯定，对终末期尿毒症病人疗效不佳。     

大型医用设备成本效益分析在HIS上的实现

介绍了大型医疗设备成本效益分析应用系统挂接HIS(“军字一号”)上的设计、功能实现及应用。该应用系统部分实现了大型医用设备的现代经济管理。     

支气管动脉灌注化疗联合直线加速器放射治疗Ⅲa期非小细胞肺癌

目的　研究支气管动脉灌注化疗联合直线加速器放射治疗Ⅲa期非小细胞肺癌 (NSCLC)的可行性及临床价值。方法　 76例NSCLC患者随机分成A、B 2组 ,A组先行 2次支气管动脉灌注化疗 (BAI) ,第 2次BAI 1～ 2周后再行直线加速器放射治疗 (RT) ;B组单纯行 2次BAI (对照组 )。结果　临床疗效 ,A组 (BAI RT)和B组 (BAI)分别为 89.47%和 60 .5 3% (Ρ <0 .0 1) ;1、3年生存率 ,A、B组分别为 81.5 8%、5 0 .0 0 %和 60 .5 3%、2 1.0 5 % ( 0 .0 1<Ρ <0 .0 5 )。结论　支气管动脉灌注化疗联合直线加速器放射治疗Ⅲa期非小细胞肺癌的临床疗效和患者 1、3年生存率均显著提高     

Failure of intensive chemotherapy in poor prognosis non-Hodgkin's lymphoma

In an attempt to improve response and survival rates in patients with non-Hodgkin's lymphoma, a relatively intense six drug regimen MATCOP was developed comprising four-weekly cycles of methotrexate (100mg/m², IV_Y day 8), Adriamycin (30mg/m², IV_Y days 1,2), teniposide (75 mg/rn², IV, day 1), cyclophophamide (300 mg/m², po, days one to five), Oncovin (1.4 mg/m², IV: maximum 2 mg, days 8,15) and prednisolone (100 mg, po, days one to five). A randomised trial was conducted comparing MATCOP with the standard CHOP regimen, comprising three-weekly cycles of cyclophosphamide (750 mg/m², IV, day 1), Adriamycin (50 mg/m², IV, day 1), Oncovin (1.4 mg/m² IV: maximum 2 mg, day 1) and prednisolone (100 mg, PO, days two to six). Eighty patients with large cell lymphoma, diffuse mixed small cleaved and large cell lymphoma or diffuse small cleaved cell lymphoma were randomised, 47 to MATCOP and 33 to CHOP. MATCOP patients experienced increased granulocytopenia, thrombocytopenia (p 0.0001), mucositis (p= 0.002) and infections (p= 0.01) compared to CHOP patients. Complete response rates were similar: 66% for MATCOP patients and 61% for CHOP patients. There were no apparent differences in the time to relapse for patients achieving CR, the time to treatment failure or the overall survival time. Thus despite an increase in toxicity, the more intense regimen MATCOP failed to confer any therapeutic benefit compared with the standard CHOP regimen. Survival was not influenced but toxicity was increased by dose intensification. (Aust NZ J Med 1992; 22: 123–128.)     

β-七叶皂苷钠治疗高温高湿环境下重型颅脑伤的疗效观察

目的探讨β-七叶皂苷钠治疗高温高湿环境下重型颅脑伤的效果。方法高温高湿环境(气温≥35℃,相对温度≥80%)下,100例重型颅脑损伤患者随机分成β-七叶皂苷钠治疗组(50例)和对照组(50例),观察治疗早期患者生命体征、颅内压(ICP)、头颅CT、经颅多普勒(TCD)变化和远期疗效,对两组结果进行比较。结果治疗组,早期患者呼吸循环较快恢复稳定,呼吸异常率26%,心律异常率26%;伤后10d颅内压显著升高率和重型脑水肿率与对照组比较均明显减少(P<0.01);治疗组TCD结果血流速度接近正常;伤后6个月恢复良好率显著高于对照组(P<0.05),重残及死亡率明显低于对照组(P<0.05)。结论β-七叶皂苷钠可以降低高温高湿环境下重型颅脑伤患者颅内压升高幅度,缩短昏迷时间,降低伤残率,促进患者神经功能恢复,改善预后,使用安全,治疗过程中未见副作用。